Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma
Open Access
- 3 March 2025
- journal article
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100081
Abstract
No abstract availableKeywords
Funding Information
- Cilag
This publication has 31 references indexed in Scilit:
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaJournal of Hematology & Oncology, 2016
- Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligibleAnnals of Hematology, 2015
- Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical developmentTherapeutic Advances in Hematology, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsHaematologica, 2011
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Median follow-up in clinical trials.Journal of Clinical Oncology, 1991